pharmaceutical combination for simultaneous, separate or sequential administration and uses of pharmaceutical combinations and a phosphorylation site inhibitor on ck2 substrates and a pharmaceutically acceptable cytostatic

摘要

PHARMACEUTICAL COMBINATION FOR SIMULTANEOUS, SEPARATE OR SEQUENTIAL ADMINISTRATION AND USES OF PHARMACEUTICAL COMBINATIONS AND A PHOSPHORILATION SITE INHIBITOR AND A CYPOSTHETIC PHARMACEUTICAL INHIBITOR CASE PRESENTATION A PHARMACEUTICAL INHIBITOR CASE 2 (called P 15) and cytostatics used in cancer chemotherapy which are administered simultaneously, separately or sequentially. Preferred cytostatics are platinum, taxanes, Vinca alkaloids, 5-fluorouracil, doxorubicin, cyclophosphamide, etoposide, mitomycin C, imatinib, iressa and velcade (vortezomib). The synergy between the P 15 peptide and the anticancer chemical compounds means that the effective concentration of each cytostatic in the combination is between one and two orders of magnitude smaller than that of cytostatics alone. Consequently, the combination described in the invention has a much lower toxicity than that reported for anticancer cytostatics which represents a crucial advantage for its use in cancer treatment. In addition, the sequentially administered combination produces chemosensitization of the cytostatic refractory tumors by pretreatment with the P 15 peptide.